Ad4-H5-Vtn

BIOLOGICAL2 trials

Sponsors

Emergent BioSolutions, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Bird FluHealthy VolunteerInfluenza

Phase 1

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

CompletedNCT01006798

Emergent BioSolutionsBird Flu, Influenza

Start: 2009-10-31End: 2011-09-30Updated: 2024-03-18

Intranasal AD4-H5-VTN as an Adenovirus Vaccine

CompletedNCT01806909

National Institute of Allergy and Infectious Diseases (NIAID)Healthy Volunteer

Start: 2013-03-06End: 2019-04-22Updated: 2019-10-07

Related Papers

A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity

Journal of Clinical Investigation2021-02-0272 citations

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study.

2013-01-29119 citations